Skip to main content

Table 2 Statistical analysis of Dot blot data showing sensitivity or specificity for autoantibody levels for ANXA1

From: Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma

Group comparison p value Summary AUC Sensitivity (%) Specificity (%)
GBC stage I and II vs Healthy 0.0177 * 0.6545 25 92.68
GBC stage IIIA vs Healthy 0.0155 * 0.7395 18.18 82.93
GBC stage IIIB vs Healthy 0.0789 ns 0.7561 33.33 87.8
GBC stage IVB vs Healthy 0.2635 ns 0.5483 17.39 92.68
GBC stage I and II vs GSD 0.0007 *** 0.724 41.67 95.83
GBC stage IIIA vs GSD 0.0009 *** 0.8011 45.45 91.67
GBC stage IIIB vs GSD 0.1043 ns 0.7153 33.33 91.67
GBC stage IVB vs GSD 0.0419 * 0.5951 17.39 91.67
GBC Early stage vs All controls 0.0005 *** 0.6919 41.67 89.89
GBC Advance stage vs All controls 0.0206 * 0.5822 15.00 89.89
LN negative vs All controls < 0.0001 *** 0.7306 30.43 89.89
LN positive vs All controls 0.2102 ns 0.5099 13.79 89.89
All cases vs All controls 0.0037 ** 0.6075 15.38 95.51
  1. GBC Gallbladder carcinomas, GSD Gallstone disease, AUC area under curve, CI confidence interval, ns not significant
\